Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer

Cancer Treatment Reviews

Volumn 34, Issue 1, 2008, Pages 13-26

  Okarvi, S M ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Bombesin; Cytotoxic peptide; Radiolabeled peptides; Radiotherapy; Somatostatin; Tumor imaging

Indexed keywords

2 PYRROLINODOXORUBICIN; AMINOCAPROIC ACID BOMBESIN[3 LYSINE FLUOROBENZOATE] F 18; AN 215; ANGIOPEPTIN; BOMBESIN ANTAGONIST; BOMBESIN DERIVATIVE; BOMBESIN[3 LYSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID] CU 64; BOMBESIN[3 LYSINE FLUOROBENZOATE] F 18; DEMOBESIN 1 TC 99M; DEPREOTIDE TC 99M; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GONADORELIN DERIVATIVE; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; LANREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID] IN 111; OCTREOTATE[3 TYROSINE] TC 99M; OCTREOTIDE; OCTREOTIDE IN 123; OCTREOTIDE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID] GA 68; OCTREOTIDE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID] IN 111; OCTREOTIDE[3 TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID] Y 90; P 829; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYCLOTRON; CYTOTOXICITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; DRUG RETENTION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG UPTAKE; HUMAN; IMAGE QUALITY; ISOTOPE LABELING; LUNG SMALL CELL CANCER; NEOPLASM; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PARAGANGLIOMA; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOISOTOPE THERAPY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID PHASE SYNTHESIS; THYROID CANCER; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BOMBESIN; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PEPTIDES; RADIOPHARMACEUTICALS; SOMATOSTATIN;

EID: 38649126592     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.07.017     Document Type: Review

References (95)

1. Okarvi S.M. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 24 (2004) 357-397
2. Heppeler A., Froidevaux S., Eberle A.N., and Maecke H.R. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7 (2000) 971-994
3. Van Den Bossche B., and Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: current status. J Clin Oncol 22 (2004) 3593-3607
4. Rufini V., Calcagni M.L., and Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 36 (2006) 228-247
5. Reubi J.C., and Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30 (2003) 781-793
6. de Jong M., Kwekkeboom D., Valkema R., and Krenning E.P. Radiolabelled peptides for tumour therapy: current status and future directions. Eur J Nucl Med 30 (2003) 463-469
7. Reubi J.C. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80 (2004) 51-56
8. Fleischmann A., Waser B., Gebbers J.O., and Reubi J.C. Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments. J Clin Endocrinol Metab 90 (2005) 4722-4729
9. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 30 (2003) 1378-1382
10. Varvarigou A., Bouziotis P., Zikos C., Scopinaro F., and De Vincentis G. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother Radiopharm 19 (2004) 219-229
11. Van de Wiele C., Dumont F., Broecke R.V., et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 27 (2000) 1694-1699
12. 1-octreotide in 194 carcinoid patients: Vienna university experience, 1993 to 1998. J Clin Oncol 18 (2000) 1331-1336
13. Hessenius C., Bäder M., Meinhold H., et al. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours. Eur J Nucl Med 27 (2000) 1684-1693
14. 99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nucl Med Biol 28 (2001) 445-450
15. 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging 30 (2003) 1134-1139
16. 99mTc-labeled minigastrin analogs. J Nucl Med 46 (2005) 1727-1736
17. Laverman P., Béhé M., Oyen W.J.G., et al. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjugate Chem 15 (2004) 561-568
18. 188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol 26 (1999) 687-693
19. 111In-labeled α-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med 48 (2007) 73-80
20. Langer M., and Beck-Sickinger A.G. Peptides as carrier for tumor diagnosis and treatment. Curr Med Chem 1 (2001) 71-93
21. Grant G.A. Synthetic peptides (2002), Oxford University Press, New York
22. Bodanszky M., and Bodanszky A. The practice of peptide synthesis (1984), Springer, Berlin
23. Wentworth Jr. P. Recent developments and applications of liquid-phase strategies in organic synthesis. Trends Biotechnol 17 (1999) 448-452
24. Stephenson K.A., Banerjee S.R., Sogbein O.O., et al. A new strategy for the preparation of peptide-targeted technetium and rhenium radiopharmaceuticals. The automated solid-phase peptide synthesis, characterization, labeling, and screening of a peptide-ligand library targeted at the formyl peptide receptor. Bioconjugate Chem 16 (2005) 1189-1195
25. Greenland W.E.P., Howland K., Hardy J., Fogelman I., and Blower P.J. Solid-phase synthesis of peptide radiopharmaceuticals using Fmoc-N-ε-(Hynic-Boc)-lysine, a technetium-binding amino acid: application to Tc-99m-labeled salmon calcitonin. J Med Chem 46 (2003) 1751-1757
26. Liu S., and Edwards S. Bifunctional chelators for therapeutic lanthanide. Bioconjugate Chem 12 (2001) 7-34
27. Susini C., and Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17 (2006) 1733-1742
28. Reubi J.C., Schär J.C., Waser B., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27 (2000) 273-282
29. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24 (2003) 389-427
30. Virgolini I., Traub T., Novotny C., et al. New trends in peptide receptor radioligands. Q J Nucl Med 45 (2001) 153-159
31. Breeman W.A.P., de Jong M., Kwekkeboom D.J., et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 28 (2001) 1421-1429
32. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20 (1993) 716-731
33. 90Y-DOTA-lanreotide: results and implications of the Mauritius trial. Semin Nucl Med 32 (2002) 148-155
34. 1]octreotide. Eur J Nucl Med 21 (1994) 328-335
35. Bakker W.H., Krenning E.P., Breeman W.A., et al. Receptor scintigraphy with radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 31 (1990) 1501-1509
36. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58 (1998) 437-441
37. Kwekkeboom D., Krenning E.P., and de Jong M. Peptide receptor imaging and therapy. J Nucl Med 41 (2000) 1704-1713
38. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 32 (2005) 1288-1295
39. 3-octreotide in patients with meningiomas. J Nucl Med 46 (2005) 763-769
40. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33 (2006) 460-466
41. 90Y-DOTATOC in association with amino acid infusion: a phase 1 study. Eur J Nucl Med 30 (2003) 207-216
42. 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31 (2004) 1257-1262
43. 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 33 (2006) 532-540
44. Wild D., Schmitt J.S., Ginj M., et al. DOTA-NOC, a high-affinity ligand for somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30 (2003) 1338-1347
45. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32 (2005) 724
46. Ginj M., Chen J., Walter M.A., Eltschinger V., Reubi J.C., and Maecke H.R. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 11 (2005) 1136-1145
47. Hocart S.J., Jain R., Murphy W.A., Taylor J.E., and Coy D.H. Highly potent cyclic disulfide antagonists of somatostatin. J Med Chem 42 (1999) 1863-1871
48. Reubi J.C., Schaer J.-C., Wenger S., et al. SST3-selective potent peptidic somatostatin receptor antagonists. Proc Natl Acad Sci USA 97 (2000) 13973-13978
49. Ginj M., Zhang H., Waser B., et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 103 (2006) 16436-16441
50. Pearson D.A., Lister-James J., McBride W.J., et al. Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studies. J Med Chem 39 (1996) 1361-1371
51. Rebollo A.C., Jimenez-Hoyuela J.M., del Valle M., Aguirre C.F., Soria C., and Velasco J.L. Lung scintigraphy with technetium-99m depreotide in the assessment of solitary pulmonary nodules. Arch Bronconeumol 40 (2004) 534-536
52. 99mTc-depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer: a pilot study. Acta Radiologica 45 (2004) 833-839
53. 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 44 (2003) 708-716
54. 99mTc-EDDA/HYNIC-TOC scintigraphy in the differential diagnosis of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 31 (2004) 1005-1010
55. 99mTc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland. Eur J Nucl Med Mol Imaging 30 (2003) 1155-1159
56. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 33 (2006) 1123-1133
57. 3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med 29 (2002) 742-753
58. 111In]DTPA-octreotide. J Nucl Med 47 (2006) 566-573
59. 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med 30 (2003) 117-122
60. 18F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 10 (2004) 3593-3606
61. 18F-labeled RGD and octreotide analogs. J Nucl Med 45 (2004) 892-902
62. 111In]octreotide. Eur J Nucl Med Mol Imaging 33 (2006) 45-52
63. 3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 10 (2004) 8674-8682
64. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 47 (2006) 492-501
65. Smith C.J., Volkert W.A., and Hoffman T.J. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 32 (2005) 733-740
66. Coy D.H., Heinz-Erian P., Jiang N.Y., et al. Probing peptide backbone function in bombesin. J Biol Chem 263 (1988) 5056-5060
67. 2 or its derivatives. Proc Natl Acad Sci USA 91 (1994) 12664-12668
68. Lin K.S., Luu A., Baidoo K.E., et al. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjugate Chem 16 (2005) 43-50
69. Maina T., Nock B.A., Zhang H., et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 46 (2005) 823-830
70. Okarvi S.M., and Jammaz I. Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent. Anticancer Res 23 (2003) 2745-2750
71. Zhang H., Chen J., Waldherr C., et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 64 (2004) 6707-6715
72. Moody T.W., Mantey S.A., Pradhan T.K., et al. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J Biol Chem 279 (2004) 23580-23589
73. Parry J.J., Andrews R., and Rogers B.E. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat 101 (2007) 175-183
74. 3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 45 (2004) 1390-1397
75. 68Ga-labeled bombesin(6-14) analog. J Nucl Med 46 (2005) 691-699
76. Zhang H., Schuhmacher J., Waser B., et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 34 (2007) 1198-1208
77. 177Lu-AMBA. Eur J Nucl Med Mol Imaging 34 (2007) 95-100
78. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 47 (2006) 1144-1152
79. 0]octreotide. J Nucl Med 44 (2003) 98-104
80. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23 (2005) 2754-2762
81. Kaltsas G.A., Papadogias D., and Grossman A.B. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 12 (2005) 683-699
82. 0]octreotide (In-OC). J Nucl Med 47 (2006) 99P abstract
83. 90Y-DOTATOC. J Nucl Med 43 (2002) 610-616
84. 3-octreotate in a rat tumor model. J Nucl Med 40 (1999) 223P abstract
85. 3]octreotate. Eur J Nucl Med 30 (2003) 417-422
86. 0]octreotide in patients. Eur J Nucl Med 28 (2001) 1319-1325
87. Schally A.V., and Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 15 (2004) 300-310
88. Schally A.V., and Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 141 (1999) 1-14
89. Magrath I.T. Targeted approaches to cancer therapy. Int J Cancer 56 (1994) 163-166
90. Kim J.A. Targeted therapies for the treatment of cancer. Am J Surg 186 (2003) 264-268
91. Nagy A., and Schally A.V. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 73 (2005) 851-859
92. Engel J.B., Schally A.V., Halmos G., Baker B., Nagy A., and Keller G. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer 104 (2005) 1312-1320
93. Keller G., Engel J.B., Schally A.V., Nagy A., Hammann B., and Halmos G. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. Int J Cancer 114 (2005) 831-835
94. Szepeshazi K., Schally A.V., Nagy A., Wagner B.W., Bajo A.M., and Halmos G. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer 98 (2003) 1401-1410
95. Engel J.B., Schally A.V., Halmos G., Baker B., Nagy A., and Keller G. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocr Relat Cancer 12 (2005) 999-1009